ArticleFrontiers in chemistry2025
Investigation of illicit pregabalin in seized samples from Saudi Arabia.
Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pregabalin (PGL) is a medication that is prescribed for controlling specific neurological-related symptoms. Due to its abuse in multiple countries, PGL has been classified as a controlled substance by authorities, including the Saudi Food and Drug Authority (SFDA). Methods: This study developed a validated ultra-performance liquid chromatography-photodiode array detector (UPLC-PDA) method to quantify PGL in 40 seized samples (35 capsules, 5 powders). A complementary liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used to detect potential adulterants. Results: The UPLC-PDA method demonstrated linearity (r = 0.9973) for PGL quantification (0.50-3.00 mg/mL), with an accuracy of 96%-102%. The RSD% values were 0.63% and 1.03% for intra-day and inter-day precision, respectively. Analysis of the five powder samples revealed a relative inconsistency in PGL content (107.91%-114.55%). Moreover, it showed higher variability in PGL content (RSD 1.16%-5.30%), suggesting possible adulteration or poor manufacturing. Furthermore, the results of the nuclear magnetic resonance (NMR) showed an acceptable purity for the powder samples. On the other hand, among 35 capsules, 5 (14.29%) exceeded pharmacopeial limits (95%-105% PGL content), while 6 (17.14%) contained <95% PGL. Discussion: These results demonstrate significant variability in PGL content and the presence of adulterants, underscoring the need for robust analytical methods in forensic chemistry. Furthermore, the LC-MS/MS method detected adulteration of PGL with codeine, paracetamol, and gabapentin in 2.9% of the analyzed capsules, suggesting custom mixing by perpetrators. In general, 31.43% of these samples failed to meet quality standards and contained substances beyond declared contents that posed toxicity risks, revealing inadequacies in illicit drug production and circulation. The UPLC-PDA method offers a rapid, validated approach for PGL quantification, while LC-MS/MS enhances adulterant detection, supporting forensic and quality control applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.